cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorCentre Jean Perrin
About this trial
The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma.
The main question it aims to answer is :
\- Does circulating DNA (cDNA) be able to detect residual disease 3 months after the end of chemoradiotherapy ? Researchers will compare detection of cDNA at 3-months and objective response (clinical and radiological).
Participants will :
* be included in the main study (Neck-TAR) * have a blood sample 1 and 3-month after the end of treatment
Eligibility criteria
Qualifiers
Patient included in NeckTAR study
Written informed consent signed for NeckTAR-IN study
Affiliation to the French social security system
Disqualifiers
None
Trial design
Treatments tested in this trial
- blood sampling
Treatment groups
59 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov